Oncimmune Holdings PLC Oncimmune Science Day
January 14 2019 - 2:00AM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
14 January 2019
14 January 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune to host Science Day at the Royal Institution
on Wednesday 23 January 2019
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
will be hosting a science day for analysts and investors at the
Royal Institution, 21 Albemarle Street, London, on Wednesday 23rd
January 2019. The event will commence at 3pm GMT followed by a
reception at 5.30pm GMT.
The afternoon will feature presentations from Dr. Adam Hill,
Chief Executive of Oncimmune; Professor Peter Johnson, Director of
the Southampton Cancer Research UK Centre; Professor Tariq Sethi,
Vice President AstraZeneca RIA TMU and Emeritus Professor of
Respiratory Medicine Kings College London; Professor Frank
Sullivan, Professor of Primary Care Medicine at the University of
St. Andrews; Dr. Cheung To, Co-founder and Chairman of Gene Group
Co. Ltd.; and Dr. Andrea Murray Chief Operational Scientist of
Oncimmune. In addition, Oncimmune's Board of Directors and members
of its newly formed Scientific Board will be in attendance.
Discussion topics will include stratified cancer care based on
tumour characteristics and the tumour micro environment focusing on
the role of autoantibodies; opportunities for collaboration and
partnerships between Chinese and UK companies arising out of the
China Precision Medicine Initiative and the experiences of two
companies forging a successful partnership; delayed presentation of
cancers in primary care and the Early Detection of Cancer of the
Lung, Scotland (ECLS) trial which will report in April 2019.
Agenda
15:00 Welcome by Meinhard Schmidt, Chairman
15:10 Introduction by Dr. Adam Hill, CEO
15:30 Immunology of Cancer - Professor Peter Johnson
15:50 Stratified Medicine and Cancer Care - Professor Tariq Sethi
16:10 Cancer Detection in Primary Care - Professor Frank Sullivan
16:30 The Opportunity in China - Dr. Cheung To & Dr. Andrea Murray
16:50 Thanks - Dr. Adam Hill, CEO
17:00 Q&A
17:30 Networking drinks and canapes
For further information, or to register for the event, please
contact Consilium Strategic Communications on
oncimmune@consilium-comms.com or +44 (0) 203 709 5700.
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5700
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of personalised immunodiagnostics for the
screening, detection and care of cancer. Oncimmune is changing how
clinicians, researchers and patients view, diagnose and treat
cancer. Our technology detects evidence of the body's natural
response to cancer, enabling detection 4 years or more before
standard clinical diagnosis. Our tests facilitate clinical
decision-making and are complementary to diagnostic technologies,
making them valuable additions to established and new care
pathways. We partner with leading developers and distributors to
make our technology available globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT(R) -Lung and EarlyCDT(R) -Liver. To date, over 155,000
tests have been performed for patients worldwide and EarlyCDT(R)
-Lung is being used in the largest-ever randomised trial for the
early detection of lung cancer using biomarkers, the National
Health Service (NHS) ECLS study of 12,210 high-risk smokers in
Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA
lab in Kansas, US and offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKNDDBBKBPDD
(END) Dow Jones Newswires
January 14, 2019 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024